235 related articles for article (PubMed ID: 12960131)
1. Peroxiredoxins in breast carcinoma.
Karihtala P; Mäntyniemi A; Kang SW; Kinnula VL; Soini Y
Clin Cancer Res; 2003 Aug; 9(9):3418-24. PubMed ID: 12960131
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma.
Kinnula VL; Lehtonen S; Sormunen R; Kaarteenaho-Wiik R; Kang SW; Rhee SG; Soini Y
J Pathol; 2002 Mar; 196(3):316-23. PubMed ID: 11857495
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of peroxiredoxin in human breast cancer.
Noh DY; Ahn SJ; Lee RA; Kim SW; Park IA; Chae HZ
Anticancer Res; 2001; 21(3B):2085-90. PubMed ID: 11497302
[TBL] [Abstract][Full Text] [Related]
4. Characterization of neural cell types expressing peroxiredoxins in mouse brain.
Jin MH; Lee YH; Kim JM; Sun HN; Moon EY; Shong MH; Kim SU; Lee SH; Lee TH; Yu DY; Lee DS
Neurosci Lett; 2005 Jun; 381(3):252-7. PubMed ID: 15896479
[TBL] [Abstract][Full Text] [Related]
5. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung.
Park JH; Kim YS; Lee HL; Shim JY; Lee KS; Oh YJ; Shin SS; Choi YH; Park KJ; Park RW; Hwang SC
Respirology; 2006 May; 11(3):269-75. PubMed ID: 16635084
[TBL] [Abstract][Full Text] [Related]
6. Oxidative/nitrosative stress and peroxiredoxin 2 are associated with grade and prognosis of human renal carcinoma.
Soini Y; Kallio JP; Hirvikoski P; Helin H; Kellokumpu-Lehtinen P; Kang SW; Tammela TL; Peltoniemi M; Martikainen PM; Kinnula VL
APMIS; 2006 May; 114(5):329-37. PubMed ID: 16725008
[TBL] [Abstract][Full Text] [Related]
7. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
8. Peroxiredoxin IV protects cells from radiation-induced apoptosis in head-and-neck squamous cell carcinoma.
Park JJ; Chang HW; Jeong EJ; Roh JL; Choi SH; Jeon SY; Ko GH; Kim SY
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1196-202. PubMed ID: 19251091
[TBL] [Abstract][Full Text] [Related]
9. p53 status is a major determinant of effects of decreasing peroxiredoxin I expression on tumor growth and response of lung cancer cells to treatment.
Chen MF; Chen WC; Wu CT; Lin PY; Shau H; Liao SK; Yang CT; Lee KD
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1461-72. PubMed ID: 17084559
[TBL] [Abstract][Full Text] [Related]
10. Involvement of peroxiredoxin IV in the 16alpha-hydroxyestrone-induced proliferation of human MCF-7 breast cancer cells.
Lee SU; Rhee Mc; Min YK; Kim SH
Cell Biol Int; 2008 Apr; 32(4):401-5. PubMed ID: 18272409
[TBL] [Abstract][Full Text] [Related]
11. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
12. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression.
Davidson B; Konstantinovsky S; Nielsen S; Dong HP; Berner A; Vyberg M; Reich R
Clin Cancer Res; 2004 Nov; 10(21):7335-46. PubMed ID: 15534110
[TBL] [Abstract][Full Text] [Related]
13. Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer.
Nakamura Y; Yasuoka H; Tsujimoto M; Yang Q; Imabun S; Nakahara M; Nakao K; Nakamura M; Mori I; Kakudo K
Clin Cancer Res; 2003 Nov; 9(14):5313-7. PubMed ID: 14614015
[TBL] [Abstract][Full Text] [Related]
14. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
[TBL] [Abstract][Full Text] [Related]
15. High-level SLP-2 expression and HER-2/neu protein expression are associated with decreased breast cancer patient survival.
Cao W; Zhang B; Liu Y; Li H; Zhang S; Fu L; Niu Y; Ning L; Cao X; Liu Z; Sun B
Am J Clin Pathol; 2007 Sep; 128(3):430-6. PubMed ID: 17709317
[TBL] [Abstract][Full Text] [Related]
16. Mouse peroxiredoxin V is a thioredoxin peroxidase that inhibits p53-induced apoptosis.
Zhou Y; Kok KH; Chun AC; Wong CM; Wu HW; Lin MC; Fung PC; Kung H; Jin DY
Biochem Biophys Res Commun; 2000 Feb; 268(3):921-7. PubMed ID: 10679306
[TBL] [Abstract][Full Text] [Related]
17. Antisense of human peroxiredoxin II enhances radiation-induced cell death.
Park SH; Chung YM; Lee YS; Kim HJ; Kim JS; Chae HZ; Yoo YD
Clin Cancer Res; 2000 Dec; 6(12):4915-20. PubMed ID: 11156252
[TBL] [Abstract][Full Text] [Related]
18. Comparison of extracellular matrix and apoptotic markers between benign lesions and carcinomas in human breast.
Vasaturo F; Sallusti E; Gradilone A; Malacrino C; Nardo T; Avagnano G; Aglianò AM; Granato T; De Vincenzi B; Coppotelli G; Marzullo A; Soda G; Simonelli L; Modesti M; Scarpa S
Int J Oncol; 2005 Oct; 27(4):1005-11. PubMed ID: 16142317
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of peroxiredoxin II confers resistance to cisplatin.
Chung YM; Yoo YD; Park JK; Kim YT; Kim HJ
Anticancer Res; 2001; 21(2A):1129-33. PubMed ID: 11396151
[TBL] [Abstract][Full Text] [Related]
20. Peroxiredoxin I and II inhibit H2O2-induced cell death in MCF-7 cell lines.
Bae JY; Ahn SJ; Han W; Noh DY
J Cell Biochem; 2007 Jul; 101(4):1038-45. PubMed ID: 17163455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]